ReviewNature reviews. Neurology2011
Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.
Review in Nature reviews. Neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The risk of ischemic stroke in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis.Clinical rheumatology · 2021Pooled it
- IL-17-driven transcriptional programs in muscle fibroblasts are not required for pathogenesis in murine anti-histidyl-tRNA synthetase (Jo-1) myositis.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Early detection and intervention in dermatomyositis: current evidence and clinical implications.Clinical rheumatology · 2026Review
- Autoantibodies as Precision Tools in Connective Tissue Diseases: From Epiphenomenon to Endophenotype.Antibodies (Basel, Switzerland) · 2026Review
- Malignancy in anti-synthetase syndrome: clinical features and prognostic impact from a multicenter retrospective study.Frontiers in medicine · 2026Article
- Next-generation clinically relevant antibody detection: Unlocking electrochemical biosensors for critical disease management.Acta pharmaceutica Sinica. B · 2025Review
- Idiopathic inflammatory myopathies lack neutralising autoantibodies to type- I, II and III interferons.RMD open · 2025Observational
- Beyond the Blot: Diagnostic Challenges in Atypical Dermatomyositis With Overlapping Myasthenia Gravis.Cureus · 2025Article
- When should a neonatologist consult a rheumatologist?European journal of pediatrics · 2025Review
- Drug-induced dermatomyositis: a pharmacovigilance study of the FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- Statin-induced immune-mediated necrotizing myopathy with concomitant increase of anti-HMGCR and anti-ACHR antibodies.Rheumatology international · 2024Review
- Prognostic factors of fungal infection in anti-melanoma differentiation-associated gene 5 antibody-positive associated interstitial lung disease.Clinical rheumatology · 2024Article
- Applicability of a serodiagnostic line blot for idiopathic inflammatory myopathy: the muscle biopsy is not all.Frontiers in neurology · 2024Article
- Immune-mediated necrotizing myopathy: Report of two cases.World journal of clinical cases · 2023Article
- Article
- Assessing the diagnostic value of a potential screening tool for detecting early interstitial lung disease at the onset of inflammatory rheumatic diseases.Arthritis research & therapy · 2022Article
- Diagnosing lung involvement in inflammatory rheumatic diseases-Where do we currently stand?Frontiers in medicine · 2022Review
- Autoantibodies in the pathogenesis of idiopathic inflammatory myopathies: Does the endoplasmic reticulum stress response have a role?Frontiers in immunology · 2022Review
- Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population.Frontiers in medicine · 2022Article
- Performance of ENMC and EULAR/ACR classification systems applied to a single tertiary center cohort of dermatomyositis patients.Neurological research and practice · 2021Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The different autoimmune myopathies-for example, dermatomyositis, polymyositis, and immune-mediated necrotizing myopathies (IMNM)-have unique muscle biopsy findings, but they also share specific clinical features, such as proximal muscle weakness and elevated serum levels of muscle enzymes. Furthermore, around 60% of patients with autoimmune myopathy have been shown to have a myositis-specific autoantibody, each of which is associated with a distinct clinical phenotype. The typical clinical presentations of the autoimmune myopathies are reviewed here, and the different myositis-specific autoantibodies, including the anti-synthetase antibodies, dermatomyositis-associated antibodies, and IMNM-associated antibodies, are discussed in detail. This Review also focuses on a newly recognized form of IMNM that is associated with statin use and the production of autoantibodies that recognize 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the pharmacological target of statins. The contribution of interferon signaling to the development of dermatomyositis and the potential link between malignancies and the initiation of autoimmune myopathies are also assessed.
Indexed as
Identifiers
21654717What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.